IPRATROPIUM BROMIDE Drug Patent Profile
✉ Email this page to a colleague
When do Ipratropium Bromide patents expire, and when can generic versions of Ipratropium Bromide launch?
Ipratropium Bromide is a drug marketed by Actavis Mid Atlantic, Apotex Inc, Bausch, Landela Pharm, Luoxin Aurovitas, Nephron, Norvium Bioscience, Ritedose Corp, Roxane, Sun Pharm, Teva Pharms Usa, Watson Labs, Zennova, Amneal, Aurobindo Pharma Usa, and Hikma. and is included in twenty-three NDAs.
The generic ingredient in IPRATROPIUM BROMIDE is ipratropium bromide. There are eight drug master file entries for this compound. Eighteen suppliers are listed for this compound. Additional details are available on the ipratropium bromide profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Ipratropium Bromide
A generic version of IPRATROPIUM BROMIDE was approved as ipratropium bromide by RITEDOSE CORP on January 26th, 2001.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for IPRATROPIUM BROMIDE?
- What are the global sales for IPRATROPIUM BROMIDE?
- What is Average Wholesale Price for IPRATROPIUM BROMIDE?
Summary for IPRATROPIUM BROMIDE
| US Patents: | 0 |
| Applicants: | 16 |
| NDAs: | 23 |
| Finished Product Suppliers / Packagers: | 17 |
| Raw Ingredient (Bulk) Api Vendors: | 69 |
| Clinical Trials: | 85 |
| Patent Applications: | 4,074 |
| DailyMed Link: | IPRATROPIUM BROMIDE at DailyMed |
Recent Clinical Trials for IPRATROPIUM BROMIDE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Oregon Health and Science University | Phase 2 |
| University at Buffalo | Phase 2 |
| Wake Forest University Health Sciences | Phase 2 |
Pharmacology for IPRATROPIUM BROMIDE
| Drug Class | Anticholinergic |
| Mechanism of Action | Cholinergic Antagonists |
Medical Subject Heading (MeSH) Categories for IPRATROPIUM BROMIDE
Anatomical Therapeutic Chemical (ATC) Classes for IPRATROPIUM BROMIDE
Paragraph IV (Patent) Challenges for IPRATROPIUM BROMIDE
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| ATROVENT HFA | Inhalation Aerosol | ipratropium bromide | 0.21 mg/Inh | 021527 | 1 | 2023-12-29 |
US Patents and Regulatory Information for IPRATROPIUM BROMIDE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Actavis Mid Atlantic | IPRATROPIUM BROMIDE | ipratropium bromide | SOLUTION;INHALATION | 075111-001 | Apr 22, 1999 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Aurobindo Pharma Usa | IPRATROPIUM BROMIDE | ipratropium bromide | SPRAY, METERED;NASAL | 075552-001 | Mar 31, 2003 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Norvium Bioscience | IPRATROPIUM BROMIDE | ipratropium bromide | SOLUTION;INHALATION | 074755-001 | Jan 10, 1997 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
